RECRUITING

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

Conditions

Alzheimer Disease Inflammation PET scans Cognitive Impairment Posterior Cortical Atrophy Logopenic Variant Primary Progressive Aphasia Amnestic Alzheimer's Disease MK-6240 Mild Cognitive Impairment

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer's disease and/or other related dementias to participate. This includes patients with: * Mild Cognitive Impairment * Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties * Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties * Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties * The investigators are also enrolling older adults with normal visual, language, and memory function.

Official Title

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

Quick Facts

Study Start:2020-11-17

Study Completion:2026-05-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04576793

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Age 50 and over at time of screening. 2. At screening, must have no cognitive impairment, or meet criteria for amnestic Alzheimer's disease, posterior cortical atrophy, or logopenic variant primary progressive aphasia. Diagnoses will be made based on history, exam, neuropsychological testing, brain MRI, and consensus diagnosis. 3. Patients must have Clinical Dementia Rating scale score of 0.5 or 1 at enrollment. Controls must have Clinical Dementia Rating scale score of 0 at enrollment. 4. Subjects unable to provide informed consent must have a surrogate decision maker. 5. Written and oral fluency in English or Spanish. 6. Able to participate in all scheduled evaluations and to complete all required tests and procedures. 7. In the opinion of the PI, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.	1. Past or present history of a brain disorder other than Alzheimer's disease (including presence of cortical infarct on MRI even in absence of clinical stroke). 2. Serious medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries. 3. Contraindication to MRI scanning. 4. Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.). 5. Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits. 6. Exact medication exclusions are up to the discretion of the PI in consultation with the MD liaison.

Inclusion Criteria

Exclusion Criteria

1. Age 50 and over at time of screening.
2. At screening, must have no cognitive impairment, or meet criteria for amnestic Alzheimer's disease, posterior cortical atrophy, or logopenic variant primary progressive aphasia. Diagnoses will be made based on history, exam, neuropsychological testing, brain MRI, and consensus diagnosis.
3. Patients must have Clinical Dementia Rating scale score of 0.5 or 1 at enrollment. Controls must have Clinical Dementia Rating scale score of 0 at enrollment.
4. Subjects unable to provide informed consent must have a surrogate decision maker.
5. Written and oral fluency in English or Spanish.
6. Able to participate in all scheduled evaluations and to complete all required tests and procedures.
7. In the opinion of the PI, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.

1. Past or present history of a brain disorder other than Alzheimer's disease (including presence of cortical infarct on MRI even in absence of clinical stroke).
2. Serious medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries.
3. Contraindication to MRI scanning.
4. Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.).
5. Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits.
6. Exact medication exclusions are up to the discretion of the PI in consultation with the MD liaison.

Contacts and Locations

Study Contact

Anna Smith

CONTACT

212-305-9079

as6545@cumc.columbia.edu

Diana S. Guzman

CONTACT

212-305-9079

dsg2158@cumc.columbia.edu

Principal Investigator

Patrick J. Lao, PhD

PRINCIPAL_INVESTIGATOR

Columbia University

Study Locations (Sites)

Columbia University Irving Medical Center

New York, New York, 10032

United States

Collaborators and Investigators

Sponsor: Patrick Lao

Patrick J. Lao, PhD, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-11-17

Study Completion Date2026-05-31

Study Record Updates

Study Start Date2020-11-17

Study Completion Date2026-05-31

Terms related to this study

Keywords Provided by Researchers

Inflammation
PET scans
Cognitive Impairment
Posterior Cortical Atrophy
Logopenic Variant Primary Progressive Aphasia
Amnestic Alzheimer's Disease
MK-6240
Mild Cognitive Impairment

Additional Relevant MeSH Terms

Alzheimer Disease